Related references
Note: Only part of the references are listed.An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer
Chunmeng Zhang et al.
AMERICAN JOURNAL OF SURGERY (2022)
Socioeconomic Disparities in Pancreas Cancer Resection and Survival in the Veterans Health Administration
Jonathan Pastrana Del Valle et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review
Annabelle L. Fonseca et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy
Colin Hill et al.
CANCER MEDICINE (2022)
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas The A021501 Phase 2 Randomized Clinical Trial
Matthew H. G. Katz et al.
JAMA ONCOLOGY (2022)
Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis
Atsushi Oba et al.
BRITISH JOURNAL OF SURGERY (2022)
Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma
George Molina et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation
Yurie Sekigami et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Patients with Low-Risk Pathology
Elizabeth J. Olecki et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis
Aileen Deng et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pancreatic Adenocarcinoma, Version 2.2021
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes
Jon M. Harrison et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma
Giampaolo Perri et al.
ANNALS OF SURGERY (2020)
Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer
Akhil Chawla et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Danielle R. Heller et al.
JAMA SURGERY (2020)
Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Jordan M. Cloyd et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
Syed A. Ahmad et al.
ANNALS OF SURGERY (2020)
The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
Axel Bengtsson et al.
SCIENTIFIC REPORTS (2020)
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment
Stijn van Roessel et al.
JAMA ONCOLOGY (2020)
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P. Janssen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Benedikt Kaufmann et al.
DIGESTIVE SURGERY (2019)
The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Akram Pourshams et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis
Ravi Shridhar et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma
Florence K. Keane et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection
Giovanni Marchegiani et al.
EUROPEAN RADIOLOGY (2018)
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma
Mathilde Wagner et al.
EUROPEAN RADIOLOGY (2017)
Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification
J. W. Gilbert et al.
ANNALS OF ONCOLOGY (2017)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer
Mia Shapiro et al.
JAMA SURGERY (2016)
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
Cristina R. Ferrone et al.
ANNALS OF SURGERY (2015)
Updated Long-Term Outcomes and Prognostic Factors for Patients With Unresectable Locally Advanced Pancreatic Cancer Treated With Intraoperative Radiotherapy at the Massachusetts General Hospital, 1978 to 2010
Sophie Cai et al.
CANCER (2013)
An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment
Christophe Cassinotto et al.
EUROPEAN JOURNAL OF RADIOLOGY (2013)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
Matthew H. G. Katz et al.
CANCER (2012)
Racial Differences in Cancer Specialist Consultation, Treatment, and Outcomes for Locoregional Pancreatic Adenocarcinoma
Melissa M. Murphy et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Mark P. Callery et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Borderline resectable pancreatic cancer: The importance of this emerging stage of disease
Matthew H. G. Katz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
National failure to operate on early stage pancreatic cancer
Karl Y. Bilimoria et al.
ANNALS OF SURGERY (2007)
Long-term results of Intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer
CG Willett et al.
ANNALS OF SURGERY (2005)
Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy - A multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer
S Alfieri et al.
ARCHIVES OF SURGERY (2001)
Share Paper
